Time for a Clinical Trial Revolution – Complex Innovative Design (CID) Cancer Trials

This 1-hour webinar will review a published consensus statement from the British Journal of Cancer (BJC), looking at recommendations for effective delivery of Complex Innovative Design (CID) cancer trials.

The traditional cancer drug development pathway is being superseded by trials that address multiple clinical questions. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret.

Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford and Alain Thibault, Chairman Simbec-Orion Oncology Advisory Board, will review the changing landscape and the need for a clinical trials revolution in early phase oncology drug development. They will also review the operational recommendations and practical considerations for delivering CID cancer trials.

This webinar will cover:

• • The changing landscape of oncology drug development – safety, toxicity and efficacy in biomarker selected patient cohorts and other agents 
  • Trial planning & design – stakeholder engagement, engagement with regulators
  • Protocol development & structure  – identifying adaptations
  • Data & databases – defining the end of the trial 
  • Risk assessment & monitoring – financial and operational, including source data verification
  • Trial management – the importance of compliance and communication in managing multiple cohorts from multiple parties
  • Statistical considerations – experience and flexibility 

Speakers

Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford

Following medical training and subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University and held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and became Director of Imperial’s Early Cancer Trials Unit and established her laboratory studying the dysregulation of mRNA translation in cancer. She has been chief or principal investigator for a number of national and international clinical studies.

Message Presenter

Alain Thibault, Chairman, Simbec-Orion Oncology Advisory Board

Alain is a medical oncologist and a renowned expert in first-in-man trials and oncology drug development. He has broad pharma experience in overseeing clinical programs from the preclinical/translational stage to IPO at the director, VP, and CMO levels in the US and EU (Roche, Janssen, Regeneron, arGEN-X). His area of expertise also includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies). Most recently, he focused on immuno-oncology development targeting co-stimulatory receptors and modification of the tumor micro-environment. His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval. Alain also has senior corporate-level experience with board presentations/communications and fund-raising.

Message Presenter